Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC-004 + ABBV-181
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SC-004 + ABBV-181 is an investigational **combination therapy** under clinical development for the treatment of advanced solid tumors, primarily epithelial ovarian, fallopian tube, primary peritoneal, and endometrial cancers. **SC-004** is an antibody-drug conjugate (ADC) developed by Stemcentrx (now part of AbbVie), while **ABBV-181** (also known as budigalimab) is a humanized IgG1 monoclonal antibody that targets the programmed cell death protein 1 (**PD-1**) immune checkpoint. The combination is designed to leverage the direct cytotoxic activity of SC-004 against cancer cells with the immune-activating checkpoint inhibition of ABBV-181, potentially enhancing anti-tumor efficacy. Clinical trials of this combination were terminated at Phase 1.
- Other names
- budigalimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SC-004 + ABBV-181.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC-004 + ABBV-181.